- PR Newswire•17 hours ago
MOUNTAIN VIEW, Calif., Oct. 27, 2016 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its third quarter 2016 financial results after the market closes on Thursday, ...
- PR Newswire•17 days ago
MOUNTAIN VIEW, Calif., Oct. 11, 2016 /PRNewswire/ -- IRIDEX Corporation (IRIX) today reported preliminary revenues of approximately $9.6 to $9.7 million for the third quarter ended October 1, 2016 compared to prior revenue guidance of $11.0 to $11.3 million. While demand for the Company's new flagship Cyclo G6™ laser platform for glaucoma remained strong, revenues of certain retina products were below expectations although the Company ended the third quarter with a record high in back orders. G6 Platform Update - For the 2016 third quarter, the Company sold approximately 90 Cyclo G6™ glaucoma laser systems and shipped approximately 7,000 G6 probes. The G6 platform is rapidly transforming our business and the treatment of glaucoma as evidenced by continued strong market acceptance of our products and clinical feedback from our customers," stated William A. Moore, President and CEO.
- PR Newswire•2 months agoIRIDEX Announces Long-Term Glaucoma Efficacy Data for Patients Treated with MicroPulse® P3 Probe Technology
MOUNTAIN VIEW, Calif., Sept. 7, 2016 /PRNewswire/ -- IRIDEX Corporation (IRIX), a leading global provider of innovative laser systems, delivery devices and consumables in ophthalmology, today announced that data on its MicroPulse® P3 (MP3) device powered by the same proprietary MicroPulse laser technology in the IRIDEX Cyclo G6TM glaucoma laser system show long-term benefits for patients with refractory glaucoma. The data were originally presented at the European Glaucoma Society (EGS) Meeting on June 19-22, 2016, in Prague, Czech Republic. The data, presented by Maria Cecilia Aquino, M.D., and Paul Chew, M.D., and titled "Long-term Efficacy of MicroPulse Diode Transscleral Cyclophotocoagulation in the Treatment of Refractory Glaucoma," were the results of retrospective case studies that aimed to evaluate and present the long-term efficacy of MicroPulse transscleral cyclophotocoagulation (MPCPC) in subjects with refractory glaucoma treated from a prior prospective trial concluded in 2014.
IRIDEX Corporation (IRIX)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
|Bid||6.47 x 200|
|Ask||18.75 x 100|
|Day's Range||12.73 - 13.19|
|52wk Range||7.50 - 16.64|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||198.46|
|Avg Vol (3m)||24,267|
|Dividend & Yield||N/A (N/A)|